Impact of MDM2 promoter SNP55 (rs2870820) on risk of endometrial and ovarian cancer-Reference-Cited by-同舟云学术

Impact of MDM2 promoter SNP55 (rs2870820) on risk of endometrial and ovarian cancer

Published:2021-02-28 Issue:4 Volume:26 Page:302-308
ISSN:1354-750X
Container-title:Biomarkers
language:en
Short-container-title:Biomarkers

Author:

Helwa Reham¹²,Gansmo Liv B.¹²,Bjørnslett Merete³⁴,Halle Mari Kyllesø⁵⁶,Werner Henrica M. J.⁵⁶,Romundstad Pål⁷,Hveem Kristian⁸,Vatten Lars⁷,Dørum Anne⁹,Lønning Per E.¹²,Knappskog Stian¹²^ORCID

Affiliation:

1. K.G. Jebsen Center for Genome-Directed Cancer Therapy, Department of Clinical Science, University of Bergen, Bergen, Norway

2. Department of Oncology, Haukeland University Hospital, Bergen, Norway

3. Department of Molecular Oncology, Oslo University Hospital Radium Hospitalet, Oslo, Norway

4. Institute for Cancer Research, University of Oslo, Oslo, Norway

5. Department of Gynecology and Obstetrics, Haukeland University Hospital, Bergen, Norway

6. Centre for Cancer Biomarkers (CCBIO), Department of Clinical Science, University of Bergen, Bergen, Norway

7. Department of Public Health, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway

8. K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway

9. Department of Gynecologic Oncology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway

Funder

Norwegian Cancer Society

Norwegian Health Region West

Norwegian Research Council

Bergen Research Foundation

K.G. Jebsen Foundation

Publisher

Informa UK Limited

Subject

Health, Toxicology and Mutagenesis,Clinical Biochemistry,Biochemistry

Link